litlas
Log inCreate account

M. Dror Michaelson

Active 1993–2025

76
Papers
25,799
Citations
59
h-index
74
i10-index

Citations

Citations per year for M. Dror Michaelson1956: 2 citations1991: 1 citations1994: 2 citations1995: 11 citations1996: 9 citations1997: 20 citations1998: 10 citations1999: 12 citations2000: 12 citations2001: 10 citations2002: 6 citations2003: 1 citations2004: 7 citations2005: 13 citations2006: 85 citations2007: 211 citations2008: 236 citations2009: 321 citations2010: 292 citations2011: 246 citations2012: 190 citations2013: 220 citations2014: 171 citations2015: 155 citations2016: 158 citations2017: 169 citations2018: 180 citations2019: 614 citations2020: 628 citations2021: 536 citations2022: 402 citations2023: 375 citations2024: 557 citations2025: 250 citations2026: 9 citations1957–1990: no citations, so these years are not shown1992–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,034 citing papers, 27.5% of this breakdownChina: 668 citing papers, 9% of this breakdownItaly: 487 citing papers, 6.6% of this breakdownUnited Kingdom: 454 citing papers, 6.1% of this breakdownFrance: 428 citing papers, 5.8% of this breakdownCanada: 339 citing papers, 4.6% of this breakdownGermany: 339 citing papers, 4.6% of this breakdownJapan: 268 citing papers, 3.6% of this breakdownSpain: 250 citing papers, 3.4% of this breakdownNetherlands: 206 citing papers, 2.8% of this breakdownAustralia: 149 citing papers, 2% of this breakdownSwitzerland: 130 citing papers, 1.7% of this breakdown
0%27.5%Other 22.3%

Institutions

Fields

  • Medicine71.3%
  • Biochemistry, Genetics and Molecular Biology21.1%
  • Immunology and Microbiology2.7%
  • Neuroscience1.4%
  • Computer Science0.7%
  • Engineering0.6%
  • Other2.2%

Topics

  • Renal cell carcinoma treatment14.7%
  • Renal and related cancers4.7%
  • Bladder and Urothelial Cancer Treatments4.1%
  • Cancer Immunotherapy and Biomarkers3.8%
  • Cancer Genomics and Diagnostics3.8%
  • Angiogenesis and VEGF in Cancer3.4%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Payal Kapur, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2022 cited by 655

  2. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

    Authors: Robert J. Motzer, Thomas E. Hutson, Hilary Glen, M. Dror Michaelson, Ana M. Molina, Timothy Eisen, Jacek Jassem, Jakub Żołnierek, Jose Pablo Maroto, Begoña Mellado, Bohuslav Melichar, Jiří Tomášek, Alton B. Kremer, Hanjoo Kim, Karen Wood, Corina E. Dutcus, James Larkin - The Lancet Oncology 2015 cited by 943

  3. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin - New England Journal of Medicine 2007 cited by 5,756

  4. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

    Authors: Pier Vitale Nuzzo, Jacob E. Berchuck, Keegan Korthauer, Sándor Spisák, Amin H. Nassar, Sarah Abou Alaiwi, Ankur Chakravarthy, Shu Yi Shen, Ziad Bakouny, Francesco Boccardo, John A. Steinharter, Gabrielle Bouchard, Catherine Curran, Wenting Pan, Sylvan C. Baca, Ji-Heui Seo, Gwo‐Shu Mary Lee, M. Dror Michaelson, Steven L. Chang, Sushrut S. Waikar, Guru Sonpavde, Rafael A. Irizarry, Mark M. Pomerantz, Daniel D. De Carvalho, Toni K. Choueiri, Matthew L. Freedman - Nature Medicine 2020 cited by 292

  5. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

    Authors: Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch - Nature Medicine 2021 cited by 294

  6. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

    Authors: Alexandre R. Zlotta, Leslie Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil Fleshner, Girish S. Kulkarni, Michael A.S. Jewett, Robert G. Bristow, Charles Catton, Alejandro Berlín, Srikala S. Sridhar, Anne Schuckman, Adam S. Feldman, Matthew Wszolek, Douglas M. Dahl, Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, David T. Miyamoto, Anthony L. Zietman, William U. Shipley, Peter Chung, Siamak Daneshmand, Jason A. Efstathiou - The Lancet Oncology 2023 cited by 245

  7. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma

    Authors: Bradley A. McGregor, Guru Sonpavde, Lucia Kwak, Meredith M. Regan, Xīn Gào, H. Hvidsten, Charlene Mantia, Xiao X. Wei, J.E. Berchuck, Stephanie Berg, Praful Ravi, M. Dror Michaelson, Toni K. Choueiri, Joaquim Bellmunt - Annals of Oncology 2023 cited by 86

  8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

    Authors: Nicholas J. Giacalone, William U. Shipley, R.H. Clayman, Andrzej Niemierko, Michael Drumm, Niall M. Heney, M. Dror Michaelson, Richard J. Lee, Philip J. Saylor, Matthew Wszolek, Adam S. Feldman, Douglas M. Dahl, Anthony L. Zietman, Jason A. Efstathiou - European Urology 2017 cited by 400

  9. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

    Authors: Toni K. Choueiri, David F. McDermott, Jaime R. Merchan, Todd M. Bauer, Robert A. Figlin, Elisabeth I. Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'souza, Zhao Song, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi - The Lancet Oncology 2023 cited by 98

  10. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Authors: Brian I. Rini, Bernard Escudier, Piotr Tomczak, А. Д. Каприн, Cezary Szczylik, Thomas E. Hutson, M. Dror Michaelson, В. А. Горбунова, Martin Gore, И. Г. Русаков, Sylvie Négrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J. Motzer - The Lancet 2011 cited by 1,849

  11. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 cited by 2,189

  12. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Authors: Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Daniel J. George, Michael J. Morris - Journal of Clinical Oncology 2017 cited by 715

  13. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

    Authors: Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel J. George, Michael J. Morris - European Journal of Cancer 2018 cited by 400

  14. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Authors: Robert J. Motzer, Bernard Escudier, Piotr Tomczak, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Stéphane Oudard, Martin Gore, Jamal Tarazi, Subramanian Hariharan, Connie Chen, Brad Rosbrook, Sinil Kim, Brian I. Rini - The Lancet Oncology 2013 cited by 745

  15. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024

    Authors: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, H.P. Bagshaw, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew J. Gunn, Naomi B. Haas, Michael P. Johnson, Payal Kapur, Jennifer King, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Randy F. Sweis, Matthew R. Zibelman, Ryan Schonfeld, MaryElizabeth Stein, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 cited by 166

  16. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

    Authors: Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon J. Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Christos E. Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley G. Somer, Jeffrey A. Sosman, Mary A. Dwyer, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2020 cited by 259

  17. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

    Authors: David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albigès, Neeraj Agarwal, Thai H. Ho, Jiaxi Song, Jean‐Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta K. Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, Sabina Signoretti - Clinical Cancer Research 2016 cited by 228

  18. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

    Authors: Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole, Charles G. Drake, Sabina Signoretti, Mahmut Akgül, Nicholas Baniak, Elsa M. Li-Ning, Matthew B. Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Z. Kaimakliotis, Yasser Ged, Phillip M. Pierorazio, E. Jason Abel, Mehmet Asım Bilen, Kenneth Ogan, Helen Moon, Krishna Ramaswamy, Eric A. Singer, Tina Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E. Delacroix, Mark J. Waples, Andrew James, Peng Wang, Toni K. Choueiri, M. Dror Michaelson, Anil Kapoor, Daniel Y.C. Heng, Brian Shuch, Bradley C. Leibovich, Primo N. Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert G. Uzzo, Gennady Bratslavsky, Naomi B. Haas, Michael A. Carducci - The Lancet Oncology 2024 cited by 82

  19. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

    Authors: Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri - European Journal of Cancer 2023 cited by 27

  20. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson - JAMA 2006 cited by 1,228

  21. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

    Authors: Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit Jain, Mayer Fishman - European Urology 2021 cited by 83

  22. Kidney Cancer

    Authors: Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis Levine, Kim Margolin, M. Dror Michaelson, Thomas Olencki, Роберто Пили, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang - Journal of the National Comprehensive Cancer Network 2009 cited by 470

  23. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, Brian I. Rini - Journal of Clinical Oncology 2005 cited by 1,632

  24. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam B. Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven Hancock, Michael R. Harrison, Won Kim, Christos E. Kyriakopoulos, Chad A. LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey A. Sosman, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 cited by 580